Effect of Aliskiren on Postdischarge Mortality and Heart Failure Readmissions Among Patients Hospitalized for Heart Failure
Mihai Gheorghiade(Northwestern University), Michael Böhm(Saarland University), Eldrin F. Lewis(Brigham and Women's Hospital), Faı̈ez Zannad(Centre d’Investigation Clinique Innovation Technologique de Nancy), Fabio Baschiera, Scott D. Solomon(Brigham and Women's Hospital), Anastasia Lesogor, Stephen J. Greene(Duke Medical Center), Jaco Botha, Claudio Gimpelewicz(Pfizer (United States)), Xavier Jaumont(Novartis (Switzerland)), Aldo P. Maggioni(Health Care Foundation), Tsushung A. Hua, Gregg C. Fonarow(UCLA Medical Center)
Cited by 327
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology
|Journal of the American Society of Echocardiography|2005|11.3k
The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
|New England Journal of Medicine|1999|9.1k
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC
|European Heart Journal|2012|6.9k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k